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| INTRODUCTION
One of the more common dilemmas the clinician caring for the patient with cystic fibrosis faces is the unwelcome report from the microbiology lab informing that the patient's respiratory culture contains a fungus; let us say, a species of Aspergillus, Candida, Exophiala, It is an old dilemma, but it is becoming more frequent. While the existence of allergic bronchopulmonary aspergillosis (ABPA) (and occasionally other allergic bronchopulmonary mycoses) have been recognized in cystic fibrosis (CF) for over half a century, the presence of fungi in the respiratory tract without strong evidence of an allergic response still presents this puzzle of what, if any, deleterious role such organisms might be playing. And in recent years a greater diversity of fungi has been increasingly seen in cultures, and particularly now in studies employing molecular methods to probe the respiratory microbiome.
In this review, we will marshal what incomplete and evolving evidence the literature provides to paint what we hope is a broader and more accurate picture of the scope and nature of the fungal presence in the polymicrobial ecology of the CF airway. We will propose an approach to differentiating harmless fungal colonization from clinically significant and harmful fungal infection, and review the various treatment options available. The need for cooperative research and clinical trials to place CF mycology on firmer footing is not only apparent, but urgent.
| EPIDEMIOLOGY
The understanding of the epidemiology of fungal species in the CF airway is evolving. Allergic disease associated with fungal antigens, including the best characterized such syndrome, ABPA, is beyond the scope of this review. ABPA in CF, present in up to 20% of CF patients, carries significant morbidity, and is considered in detail elsewhere. [1] [2] [3] National cystic fibrosis registry data in the USA is limited by a lack of standardization in protocols for collecting and analyzing samples. The most commonly described fungi in registry data are yeasts, specifically Candida spp., and the filamentous fungus Aspergillus. The annual report for the Cystic Fibrosis Foundation Patient Registry in 2013 noted a median prevalence of 11.9% of patients who were culture positive for Aspergillus spp., and 7.8% who were positive for Candida spp. 4 The
United Kingdom (UK) CF Registry data from 2007 to 2012 was analyzed for fungal isolates, and noted the prevalence of Aspergillus spp. increased from 6.5% in 2007 to 13 .6% in 2012. Also of note, Scedosporium spp. increased slightly from 0.07% to 0.68%. 5 The range of fungal species described in CF is expanding in concert with improved culture techniques and increased application of molecular diagnostics. Figure 1 outlines the wide spectrum of fungi which have been isolated in CF and these are grouped based on the current clinical impressions of chronicity and pathogenicity. 6 The isolation of Scedosporium spp. and Lomentospora prolificans, Exophiala dermatitidis, Trichosporon mycotoxinivorans, and Pneumocystis jirovecii is increasingly reported. Identification of P jirovecii in CF patients is described throughout the world, with regional differences appreciated.
French studies describe a prevalence of P jirovecii of 2.5-12.5%, while a cohort of Brazilian CF patients had a prevalence of 38.2%. [7] [8] [9] Three recent culture-based studies illustrate the increased prevalence of fungi isolated using fungal specific diagnostic protocols, compared to the variable diagnostic techniques used to generate CF registry data.
A recent 3-year multicenter study conducted in France, "Muco-
Fong," applied a consistent and detailed mycological protocol to CF sputum specimens. 10 In total, 243 CF pediatric and adult patients had sputum specimens that were analyzed using fungal selective media. A total of 81% of patients had at least one fungal species isolated. By far the most prevalent species identified for all age groups were Candida Figure 2 demonstrates that the prevalence of filamentous fungi isolated using fungal selective media is similar across these recent studies. [10] [11] [12] A retrospective analysis of respiratory samples from nine European CF center datasets from 2011 to 2016 supported the epidemiologic findings from these recent studies-despite variability in patient cohorts and diagnostic protocols. 13 Again C albicans was the FIGURE 1 Cystic fibrosis fungal biodiversity grouped according to frequency of isolation (x axis) and established pathogenicity (y axis). The fungi are further divided in terms of chronicity as illustrated. The most frequently isolated filamentous fungi, Aspergillus fumigatus and Scedosporium species complex, and yeast Candida albicans are highlighted. Low-chronicity genera: A. = Aspergillus; C. = Candida; E. = Exophiala; P. = Pneumocystis; R. = Rasamsonia. High-chronicity genera: A. = Aspergillus (flavus, nidulans, niger); A. = Acrophialophora (fusispora); C. = Candida; E. = Exophiala; N. = Neosartorya; P. = Pseudallescheria; S. = Scedosporium; T. = Trichosporon. Reprinted with permission of the American Thoracic Society. Copyright © 2018 American Thoracic Society. Chmiel et al 6 . Annals of the American Thoracic Society is an official journal of the American Thoracic Society FIGURE 2 Prevalence of the filamentous fungi Aspergillus, Scedosporium, and Exophiala isolated using fungal selective media in CF patients from studies in the USA, France, and Germany (data derived from Refs 10-12) most prevalent yeast found; the mean number of positive patients detected each year was between 33.8% and 77.9%. The primarily filamentous fungus isolated was A fumigatus with rates between 3.9% to 42.4%. Scedosporium/Lomentospora spp. were found to have a prevalence rate of 2-5% in the majority of countries studied.
E dermatitidis prevalence ranged between 0% and 18.3% and Trichosporon spp. was reported between 0% and 3.5%.
The prevalence of fungi in the airways of CF patients has traditionally been based on conventional fungal culture isolation and identification techniques, however, the recent application of cultureindependent molecular methods has revealed many additional fungal taxa not previously appreciated; for example, analysis of sputum specimens from adult CF patients found that more than 60% of species identified in CF airways were absent in cultures.
14 In a series of recent culture-independent studies, the most commonly identified fungal taxa included: Aspergillus spp., Candida spp. Penicillium, Malassezi, with many other rare taxa of unknown clinical significance. [14] [15] [16] Figure 3 illustrates the multitude of fungal species identified by molecular methods, and the differences that may constitute a unique lung mycobiome in CF patients. 17 
| RISK FACTORS
Existing literature highlights an array of risk factors associated with the identification of fungal species in CF specimens.
A single-center 10-year retrospective cohort study of pediatric and adult CF patients in the United States assessed risk factors for the isolation of fungi on respiratory cultures. 18 The prevalence of filamentous fungi identified was 41.3%, with A fumigatus accounting for 36.3%-consistent with other described populations. Decreased lung function was a notable risk factor for identification of filamentous fungi. For every 10% drop in forced expiratory volume in 1 s (FEV 1 ) below 100% predicted, the odds of identifying filamentous fungi was increased by 5%. This finding is supported by other studies showing the association between A fumigatus and lower FEV 1 % predicted. 19 The use of chronic oral antibiotics, and inhaled antibiotics, is associated with the isolation of fungi from sputum samples. 12, 20 In particular, chronic azithromycin therapy may be associated with increased risk for Aspergillus isolation. 20, 21 Several clinical studies have investigated the relationship between
Pseudomonas and Aspergillus with differing findings. A retrospective cohort study of children with CF examined the relationship between A fumigatus and P aeruginosa on lung function, and noted an association with lower pulmonary function. 19 In contrast, a retrospective cohort study of children and adults with CF with A fumigatus colonization found no significant difference in lung function in patients with concurrent chronic P aeruginosa.
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The association of inhaled corticosteroids and older age with fungal isolation is not quite as clearly defined-with studies showing both decreased and increased rates of fungal isolation. 18, 20, 23 Recent work also suggests white race and pancreatic insufficiency are associated with the risk of persistent Aspergillus isolation. 20 The identification of risk factors associated with the recovery of fungi in the CF respiratory tract is useful, though lung function data in particular prompts the question of whether the presence of fungi is a marker, or an etiology, for more severe or progressive disease.
| HOST-PATHOGEN INTERACTIONS
Complex host-pathogen interactions exist between innate and adaptive immune defenses of the CF lung and fungal species. Ongoing research is beginning to elucidate the many components that the influence these intricate and dynamic relationships. 24, 25 Of the fungal taxa in the CF airway, the pathogenicity and virulence factors of A fumigatus are the best described. In an excellent review Kwon-Chung and Sugui 26 explain why this species is one of the most commonly isolated. A fumigatus thrives at body temperature, but it can also tolerate wide variations in temperature, and is equipped with secondary metabolites and efflux pumps which act as adaptive defense mechanisms. In large part due to their hydrophobicity, A fumigatus conidia are particularly easy to disperse. Once dispersed, the small size mucocilliary transport, and provide an environment for a cycle of inflammation and infection. 28 Furthermore, research suggests that CFTR is a key component in directing epithelial cellular response to A fumigatus. 29 In the presence of a CFTR mutation, A fumigatus may lead to an increased inflammatory response.
Investigation of the interactions between pathogenic bacteria and fungi in the CF airways are a current topic of intense interest, particularly with respect to the relationship between Pseudomonas and
Aspergillus. In vitro work suggests competitive inhibition of A fumigatus biofilm formation by small molecules produced by P aeruginosa.
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However, the degree of inhibition seen in vitro appears to be dependent on the source, phenotype, and growth conditions of the P aeruginosa. responses are protective from infection or pathogenic to the host. 38 In this vein, recent work points to the induction of regulatory T-cells with a pro-inflammatory Th17-like phenotype in human PBMCs exposed to A fumigatus-a response that can shift the balance from a protective to deleterious effect. Toll-like receptor 2 (TLR2) and cytotoxic T-lymphocyte-associated protein 4 (CTLA4) appear to regulate the induction of T-cells, suggesting they may offer a therapeutic target. 39 Interestingly, blood basophil priming and activation has been shown in allergic but not infective phenotypes of aspergillosis in CF. 40, 41 Hope exists for the ongoing development and validation of biomarkers that can guide and monitor therapeutic interventions based on this steadily increasing understanding of fungal virulence and host-pathogen interactions.
| DIAGNOSTIC METHODS
The first step in evaluating fungi in the CF airway is a consistent and accurate approach to evaluating respiratory samples. Prior to ascribing differences in geography or patient population as risk factors for isolating fungi, first, analysis of the laboratory methods must be considered. The variability in detection of fungi is highlighted by a retrospective study which noted different prevalence rates for fungal isolation from the same cohort of patients in UK. 42 Patients from the same CF cohort had specimens processed at two centers with different mycological methods throughout the study period, leading to the understanding that laboratory methods rather than geographical or demographic features were driving the difference in prevalence.
Culture-based detection methods are the primary approach for isolating fungi. Guidelines for processing respiratory samples are not standardized, despite the importance of controlling for numerous variables that can affect successful isolation. These factors include the source of the specimen (OP swab, sputum, BAL), volume of specimen, preparation of specimen, choice of culture media, and temperature and duration of incubation. 43 The site of sampling may play an important role in the rate of isolation of fungi. A retrospective cohort analysis of pediatric CF respiratory samples compared the prevalence of A fumigatus in cough swabs, sputum, and BAL specimens. 44 BAL samples detected A fumigatus in 29% of specimens, compared to 14% of sputum specimens, and 0.8% of cough swabs. The optimal method for sampling the airway for microbiological studies continues to be refined, with consideration for the risks and benefits of more invasive techniques, and the increasing understanding of the spatial variation in upper and lower airway microbiota. 45 The volume of respiratory samples used for culture is noted to be a possible confounder in comparing prevalence rates across centers. 42 There is evidence to suggest isolation of Aspergillus is more successful with higher volume of specimen plated. 46 The properties of CF sputa pose unique challenges for diagnostic methods. The highly viscous quality of the sputum has led to the recommendation for the homogenization of specimens. A study on CF patients in Austria compared the results of mycological cultures following chemical homogenization of CF sputum to native, unprocessed sputum, and found homogenization increased sensitivity of culture detection from 72.4% to 96.2%. 47 Other work has suggested the addition of sonication to chemical homogenization of CF sputum to improve the sensitivity of Aspergillus PCR testing when compared to traditional culture. 48 The importance of fungal specific media for culture-based detection has long been described. 49 Recent work highlights the differences in prevalence rates noted by the choices of culture media.
A study comparing three laboratory methods (non-selective conventional culture, mycological culture with fungal-selective culture media supplemented with antibiotics, and direct DNA extraction from sputum samples) in 77 adults with CF in Northern Ireland revealed that conventional microbiological culture media can fail to identify fungi in the context of bacterial overgrowth. 50 In this study conventional bacterial culture isolated fungi in 18% of patients.
Specific mycological culture fared much better isolating fungi in 78% of patient samples. DNA extraction detected fungi in 100% of patients examined. The authors of the study postulated the low rate of recovery using standard culture was secondary to the overgrowth of gramnegative organisms and the relatively short length of incubation.
These findings were supported by a recent CF cohort study in the United States which compared selective fungal media to traditional bacterial culture for the identification of Aspergillus, Scedosporium, Trichosporon, and Exophiala species in adults with CF. 12 Of the 184 samples identified with one or more of these fungal species, bacterial culture detected fungal species in only 26% of these samples, with three other fungal selective media having much higher recovery rates, from 63% to 65.8%.
The recent multicenter MucoFong project in France applied a standardized mycological protocol to sputum specimens. 10 All samples were pretreated with a mucolytic, examined and plated on six semi-selective culture media, in context of the previous observations noting that the presence of antibiotics in media can play an important role. All samples were incubated for 3 weeks and checked twice weekly.
While a shorter period of incubation may be sufficient for some fungal species, emerging organisms may require much longer culture duration; ultimately the authors of the MucoFong study recommended an incubation time of 16 days. 10 However, other authors have concluded 7 days may be long enough.
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The frequency of sampling is an additional consideration. Two mycology-focused studies conducted with CF patients in France described prevalence rates of A fumigatus and S apiospermum observed. In one study, a single sputum specimen was collected, and in the other, a longitudinal design was employed with repeat sampling. In the longitudinal study, the recovery of both fungal species more than doubled.
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In addition to culture-based methods, molecular approaches are increasingly being applied and excellent reviews of molecular methods exist elsewhere. 43 Multiple polymerase chain reaction (PCR)-based techniques exist, with regional differences in implementation. PCR techniques rely upon use of internal transcribed spacer ribosomal sequences common to all fungi, followed generally by secondary analysis for species specific identification. Real-time PCR (RT-PCR) methods for single fungal species identification may increase sensitivity for detection of fungi compared to culture alone. The literature on Candida spp. parallels these variable outcomes.
C albicans, the most common species isolated, is generally thought of as non-pathogenic. This being said, when identified as a colonizer of the CF airway C albicans is associated with increased rates of decline in FEV 1 in some studies; while an association with preserved lung function was found in another study. 53, 57, 58 Two recent clinical studies of patients with A fumigatus colonization illustrate the use of pulmonary function and chest imaging to address this conundrum. is a risk factor for colonization. Then, looking forward, they described the 7-year period after colonization when the colonized group had significantly lower lung function-leading to the suggestion that colonization with A fumigatus is also associated with a more rapid decline in lung function.
A prospective study compared 16 CF patients colonized with
Aspergillus spp. with 16 matched non-Aspergillus CF patients, with respect to pulmonary function and high resolution computed tomography (HRCT). 59 The authors noted no differences in pulmonary function, however, they did find more severe mosaicism suggestive of air trapping, leading them to posit that Aspergillus infection may lead to subclinical lung parenchymal injury, and thus may suggest consideration for eradication therapy.
Taken together it appears colonization may exist without evidence of lung function decline, however, in other contexts colonization can progress to a clinical decline which is consistent with infection.
A pathologic distinction between colonization and infection in CF fungal lung disease has been described. A review of autopsies of 63 CF patients from 1982 to 1987 in the United States (Ohio) identified fungi in 14 patients. 60 The fungal species isolated included: Aspergillus spp., 
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A 2-year prospective cohort study of adults with CF in the UK set out to further characterize and classify the spectrum of aspergillosis in CF using several biomarkers. 37 The authors combined real-time quantitative PCR (RT-PCR) for Aspergillus DNA and galactomannan (GM) from sputum with serologic testing, which included total IgE (tIGE), specific A fumigatus IgE (sIGE) and specific A fumigatus IgG (sIgG). Based on these diagnostic tests, they divided patients into four groups: non-diseased, ABPA, Aspergillus sensitized, and Aspergillus bronchitis. Of the 130 patients who were triazole-naïve, 30% were described as having Aspergillus bronchitis. Patients with Aspergillus bronchitis had elevated levels for Aspergillus DNA, GM, and sIgG; and absent or low values for tIgE and sIgE. Thus, the addition of RT-PCR, GM, and sIgG to the initial diagnostic criteria for Aspergillus bronchitis may allow better discrimination between Aspergillus colonization and infection. That being said, in current clinical practice sputum processing challenges limit the application of GM and RT-PCR testing, leaving sIgG as the most promising candidate for multicenter evaluation.
A recent single center prospective study in Germany combined the clinical, microbiologic, and immunologic criteria for Aspergillus bronchitis noted in the two studies above, and applied this to a cohort of 22 CF patients. 62 Two patients (9%) met criteria for
Aspergillus bronchitis based on these definitions. Of note, neither patient had new pulmonary infiltrates on chest imaging. The authors note that the absence of longitudinal data leaves many questions about how patients may transit between different classifications over time.
In addition to bronchitis, invasive fungal disease remains a diagnostic and therapeutic challenge in CF. A recent excellent review noted that, in the absence of consensus criteria, empiric criteria to define a "highly probable" invasive pulmonary fungal infection include:
1. Increased sputum production.
2.
Multiple isolation of the same fungal species from sputum or BAL (at least two culture-positive samples in 6 months).
3. Pulmonary infiltrate(s) on chest CT scan or X-ray.
4.
Treatment failure with antibiotic therapy (two and more antibiotic treatments, duration 2 or more weeks).
5.
Unexplained lung function decline.
6. Exclusion of new/other bacteria.
7.
Exclusion of allergic ABPA. 63 Overall the risk for invasive fungal disease in CF is low, however, the CF lung transplant population is particularly vulnerable. The identification of risk factors for invasive pulmonary aspergillosis (IPA) in CF lung transplant recipients is essential. In a single-center retrospective study of 93 CF lung transplant patients in Canada, pre-transplant Aspergillus colonization was common, with 70% of patients effected. 64 Intraoperative Aspergillus culture was positive in 39% of patients, and 22% of patients went on to develop IPA posttransplant. Intraoperative isolation of Aspergillus was associated to a fourfold risk of IPA, pointing to the importance of microbiologic testing and a high level of suspicion in this high-risk group.
A marrying of microbiologic, immunologic, and clinical diagnostic criteria across the spectrum of CF fungal lung disease remains much needed. In Table 1 , we propose criteria to consider when making this challenging differential diagnosis. Aspergillus bronchitis using itraconazole has been described as beneficial, though these are small studies, with a variable duration of therapy (from 2 weeks to more than 2 years) and limited clinical outcome measures. 61, 62 Voriconazole is the first-line therapy recommended for treatment for IPA across all populations. 67 A recent consensus recommendation for the treatment of IPA in CF supported the use of voriconazole as first line therapy, with posaconazole also noted as a consideration. 63 Furthermore, in CF lung transplant patients with Aspergillus colonization the preemptive use of voriconazole therapy for 3 months was linked to a reduction in IPA. 68 Triazoles are also recommended in management of Scedosporium spp. and L prolificans, E dermatitidis and T mycotoxinivorans infections. Triazole therapies are preferable in that they are the only oral medications to treat fungi in CF. However, this class is limited by pharmacokinetic challenges which may contribute to toxicity and azole resistance. 72 Similar to other antimicrobial agents, obtaining therapeutic drug levels is of particular importance for CF patients receiving triazoles, with both subtherapeutic and supratherapeutic levels commonly described. 72, 73 The hepatic metabolism of triazoles through the cytochrome P450 While azoles are generally well tolerated, important adverse effects exist. Hepatotoxicity is the primary side effect associated with all azoles. Voriconazole is also notable for reports of vision changes, neurologic toxicity, and photosensitivity. 78 Phototoxicity is of particular concern in CF patients. 79 In the lung transplant population, voriconazole is associated with an increased risk for cutaneous squamous cell carcinoma. 80 Posaconazole may have a preferable side effect profile when compared to voriconazole, particularly with respect to photosensitivity. 81 Azole resistance in fungi is of increasing concern. Two large single center studies in Denmark and France revealed similar rates of reduced A fumigatus susceptibility to itraconazole of 4.5% (6/133) and 4.6% (6/ 131), respectively. 82, 83 Reduced susceptibilities were strongly associated with previous itraconazole therapy. In addition, there is increasing consideration for the development of azole resistance secondary to the use of fungicides in agriculture and environmental exposures. 84 Authors of the French study went on to note that isolates with reduced susceptibilities to itraconazole also had reduced susceptibility to posaconazole, and half of the isolates had reduced susceptibility to voriconazole.
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A prospective study of CF patients in Germany, which analyzed resistance patterns of Scedosporium spp. and L prolificans, noted great variability in minimum inhibitory concentrations, though overall high levels of resistance, particularly from L prolificans. 70 Voriconazole had the greatest in vitro activity of the three triazoles tested. This work suggests the importance of assessing local resistance patterns, particularly if a patient is failing to show treatment response.
The application of the polyene antimycotic amphotericin B, in both aerosolized and intravenous forms, is described in CF. Aerosolized amphotericin B is commonly used as prophylaxis in CF lung transplant patients. 68, 85 There is ongoing interest in applying this nebulized antifungal in the treatment of CF patients with ABPA, and other emerging fungal species, though this literature is limited. 86, 87 Intravenous liposomal amphotericin B is reserved for the treatment of severe invasive fungal disease, with literature again largely limited to case studies. 87 For azole-resistant A fumigatus, liposomal amphotericin B is a consideration. 63 Use of amphotericin B is limited in CF in large part secondary to the noted adverse effects which include nephrotoxicity, acute infusion-related reactions, and electrolyte abnormalities.
While many Aspergillus spp. are generally susceptible to amphotericin B, several fungal species have high levels of resistance, most notably Scedosporium spp. and T mycotoxinivorans.
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Echinocandins (caspofungin, anidulafungin, and micafungin) are commonly used to treat invasive candidiasis in non-CF patients, while in CF they are increasingly described in use as combination therapy for the management of invasive fungal disease. 87 This class is generally well tolerated with similar rates of hepatotoxicity and infusion reactions across the three drugs. In cases of azole-resistance authors have recommended combination therapy with an echinocandin in addition to triazoles. Combination therapy may also be necessary in cases of multiple simultaneous invasive fungal infections. 89 Lastly, the impact of CFTR modulators on fungi in the CF airway may hold promise. The G551D Observational (GOAL) Study followed changes is prevalence of CF airway microbes in patients before and after treatment with ivacaftor. 90 The study found that ivacaftor was associated with a reduction of culture positivity of P aeruginosa and Aspergillus spp. in the months following initiation of ivacaftor. Longer follow-up studies are in progress.
| CONCLUSIONS
With use of proper mycological culture protocols, it is now clear that fungi are present in the CF respiratory tract of most patients. A substantial minority of patients, perhaps 20%, will be adversely affected by true infection and may benefit from antifungal therapy.
The poor state of current understanding mandates a large research agenda. There is a pressing need to standardize mycology culture protocols in much the same way that the CF community has done in monitoring our patients for pathogenic bacteria. Similarly, the risks and benefits of fungal eradication protocols should be considered for evaluation in clinical trials. As the data generated from molecular detection and identification methods accumulates, we need to integrate this complex information into a broader strategic approach to fungal disease in CF. We need to more clearly understand the impact of CFTR modulator therapy upon lung microbiology including impact upon fungal colonization and infection. We need to better unravel the inter-kingdom interactions occurring in the airways of CF patients 
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